In addition, EVs released by HER2 breast cancer cells resistant to trastuzumab-dependent cell cytotoxicity display an increased level of the immunosuppressive molecules TGF-β1 and PD-L1 (programmed death-ligand 1) and are able to transfer a resistant phenotype to drug-sensitive cells [71]. This evidence concerns the gene ERBB2 and breast cancer.